Stocks · News reference
Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry
Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.The MTA details the conditions under which PegBio will
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 1:05 PM
- Checked
- Aug 13, 2026, 1:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
Read original at benzinga8-K filing — Lexaria Bioscience Corp. (LEXX)
Filed: 2026-08-17 AccNo: 0001640334-26-001384 Size: 135 KB Item 8.01: Other Events
Read original at edgarLexaria Bioscience Stock Rallies Thursday: What Investors Need to Know
Lexaria Bioscience shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio.
Read original at benzinga